VUF 8929

Drug Profile

VUF 8929

Latest Information Update: 22 Jan 2001

Price : $50

At a glance

  • Originator Free University Amsterdam
  • Class Anti-ischaemics; Ischaemic heart disorder therapies
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 22 Jan 2001 Discontinued-Preclinical for Ischaemic heart disorders in Netherlands (Unknown route)
  • 22 Jan 1998 A study has been added to the Ischaemic Heart Disease Pharmacodynamics section
  • 11 Dec 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top